Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Head of Immuno-Oncology at Gilead Sciences
Dr. Nicholas Wilson is a cancer immunologist with 15 years of antibody drug discovery and development experience, and is an expert in the area of harnessing Fc:Fc gamma receptor biology to optimize cancer immunotherapeutics. He has contributed to several foundational basic research papers in this area, including uncovering an Fc gamma receptor mechanism that drives antibody-dependent forward signaling in immune and cancer cells, as well as identifying the potential contribution of Fc gamma receptor-mediated depletion of intratumoral regulatory T cell for the anti-tumor efficacy of antibodies targeting GITR, OX40 and CTLA-4. Dr. Wilson is currently head of Immuno-Oncology Research at Gilead Sciences in California, and has held past positions at Novartis, Merck Serono, Agenus, CSL Limited and Genentech.